Business Context and Reporting Period
Rigel Pharmaceuticals, Inc. (RIGL) filed a Form 8-K on April 16, 2026, reporting the termination of a material definitive agreement with Eli Lilly and Company. The company is incorporated in Delaware and trades on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the contractual termination event.
Material Changes
- Agreement Termination: Eli Lilly elected to terminate the License and Collaboration Agreement dated February 18, 2021, in its entirety.
- Effective Date: The termination becomes effective on June 15, 2026.
- Scope: The agreement covered an exclusive worldwide license for ocadusertib (RIPK1 inhibitor) for non-CNS diseases and additional inhibitors for CNS diseases.
- Asset Recovery: Rigel expects to regain full rights to the licensed compounds and related programs upon termination.
Outlook, Risks, and Management Commentary
- Future Revenue Impact: Following this termination and a prior termination of the CNS disease program in November 2025, Rigel does not expect to receive future milestone payments or royalties under the Agreement.
- Current Status: The company is currently evaluating the financial and operational impact of the termination.
- Transition: Lilly's rights to the licensed compounds will cease subject to applicable transition provisions.
Investor Verification Checklist
- Confirm the exact date of termination effectiveness (June 15, 2026) and any associated transition timelines.
- Verify the status of Rigel's internal plans to re-develop or re-license ocadusertib and related compounds.
- Assess the total potential revenue loss from foregone milestones and royalties compared to prior guidance.
- Review the November 2025 termination of the CNS disease program for cumulative impact on the pipeline.